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Abstract
PURPOSE—To evaluate use of specific antiepileptic drugs (AEDs) in pregnancy in relation to 
specific birth defects.
METHODS—Using data from the National Birth Defects Prevention Study, we assessed use of 
AEDs and the risk of neural tube defects (NTDs), oral clefts (OCs), heart defects (HDs), 
hypospadias, and other major birth defects, taking specific agent, timing, and indication into 
consideration.
RESULTS—Drug-specific increased risks were observed for valproic acid in relation to NTDs 
[adjusted odds ratio (aOR), 9.7;, 95% confidence interval (CI), 3.4–27.5], OCs (aOR, 4.4; 95% CI, 
1.6–12.2), HDs (aOR, 2.0; 95% CI, 0.78–5.3), and hypospadias (aOR. 2.4; 95% CI, 0.62–9.0), and 
for carbamazapine in relation to NTDs (aOR, 5.0; 95% CI, 1.9–12.7). Epilepsy history without 
AED use did not seem to increase risk.
CONCLUSIONS—Valproic acid, which current guidelines suggest should be avoided in 
pregnancy, was most notable in terms of strength and breadth of its associations. Carbamazapine 
was associated with NTDs, even after controlling for folic acid use. Sample sizes were still too 
small to adequately assess risks of less commonly used AEDs, but our findings support further 
study to identify lower risk options for pregnant women.
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Although treatment choices for control of seizures involves consideration of a variety of 
factors, such as the type and severity of underlying illness and other patient characteristics, it 
is made even more complex when considering pregnancy (1, 2). Not only must the 
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therapeutic and adverse effects of antiepileptic drugs (AEDs) be taken into account in 
pregnant women, but risks to her fetus should be evaluated as well. Valproic acid, 
carbamazepine, phenytoin, and lamotrigine are effective AEDs, but each medication has also 
been reported to increase the risk of birth defects (3–7). The evidence to support such 
suspicions varies for each medication in terms of both the certainty and magnitude of a 
putative effect, further complicating treatment choices. Many of the studies showing 
increased birth defect risk are based on small numbers of exposed subjects. Even cohorts 
with thousands of pregnancies exposed to AEDs typically include fewer than 500 exposed to 
any specific agent and fewer than five cases of a specific malformation exposed to any 
specific agent (8, 9). It has been suggested that associations are due to the underlying 
epilepsy, rather than treatment, based on observations that a variety of different AEDs 
increase birth defect risks (3, 5–7). Also, use of more than one AED (polytherapy) is a 
possible indicator of more severe epilepsy, and risks are highest among women on 
polytherapy (7). Whether birth defects are increased among women with a history of 
seizures but no anticonvulsant use in pregnancy remains a point of controversy, but a recent 
summary of the literature concluded that there is no association (10).
The National Birth Defects Prevention Study (NBDPS) is an ongoing, multistate case-
control study (11) that offers a large data set to add to this literature on the magnitude and 
certainty of the effects of in utero exposure to specific AEDs. Using NBDPS data, we 
evaluated pregnancy exposures to the most commonly used AEDs in relation to birth defects 
overall and selected birth defect groups. In addition, the issue of confounding by indication 
was addressed by examining untreated epilepsy and the subgroup of women who used AEDs 
without a history of seizures.
PATIENTS AND METHODS
Source Population
The NBDPS ascertained population-based case subjects with birth defects and control 
subjects without birth defects in Arkansas, California, Georgia, Iowa, Massachusetts, New 
Jersey, New York, North Carolina, Texas, and Utah. Eligible cases include pregnancies 
affected with any of 30 major structural malformations but without known chromosomal or 
single-gene disorders (12). Control subjects were infants without any known birth defects 
selected from births at hospitals where cases were ascertained or by random sample of births 
in the case catchment areas. The study population included mothers of 18,631 cases with 
birth defects and 6807 non-malformed controls with expected delivery dates between 
October 1997 and December 2005, after excluding 174 cases and 61 controls with 
incomplete interviews. Women were asked if they had a history of seizures, and if so, if they 
had been told by a doctor that they had epilepsy, and whether they took any medications for 
seizures or epilepsy. The numbers of case and control mothers according to seizure history, 
epilepsy diagnosis, and AED use are shown in Figure 1. Women who reported a history of 
seizures but no diagnosis of epilepsy or AED use most likely experienced childhood febrile 
seizures only (n = 534) were excluded from analyses. In addition, women whose seizure 
history was unknown or missing (n = 25) or who reported seizure, but not epilepsy history, 
and used AEDs before or after the first trimester (n = 14) were excluded. For multivariable 
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regression analyses, subjects with incomplete socio-demographic variables were excluded (n 
= 1144). Birth defects cases were categorized into four (non–mutually exclusive) groups that 
have previously been linked to AED use in pregnancy: Neural tube defects (NTDs), oral 
clefts (OCs), heart defects (HDs), and hypospadias. Cases without any of these four defects 
constituted the “other birth defects” group. Because NTDs, OCs, HDs, hypospadias, and 
other birth defects are known to recur within families, analyses were restricted to cases and 
controls without a reported family history of the specific birth defect, resulting in varying 
numbers of controls across specific case group. After exclusions, there were 1116 cases with 
NTDs: 2460 cases with OCs, 7213 with HDs, 1214 with hypospadias, and 5113 cases with 
other birth defects. The proportion of eligible cases that participated in the interview ranged 
from 69% to 74% for specific case groups and was 66% for controls.
Antiepileptic Medications
Mothers were interviewed by telephone within 2 years of delivery with a standardized, 
computerized questionnaire that included questions about demographic, reproductive, 
medical, and behavioral factors, and whether they had ever had seizures, were told by a 
doctor they had epilepsy, if they had taken any medications, and, if so, what medication and 
when taken. All reports of AEDs were coded using the Slone Epidemiology Center Drug 
Dictionary and classified by a pharmacist. Four mutually exclusive categories of exposure 
were created: “Trimester 1” exposure included any AED use, regardless of seizure history, 2 
to 14 weeks after the last menstrual period; “Trimester 1 Non-exposed + Epilepsy” included 
reported history of epilepsy, without use of AEDs during trimester 1; “Pre/Post Use + No 
Seizure History” included AED use in the 3 months before pregnancy or in the second or 
third trimesters (but not Trimester 1) and no reported history of seizures or epilepsy; and 
“No Seizures or Use” included no reported history of seizures, epilepsy, or AED use during 
the 3 months before through the end of pregnancy.
Statistical Analyses
Odds ratios (OR) and 95% confidence intervals (CIs) for birth defect outcomes (overall and 
isolated) were calculated for three exposure groups with No Seizures or Use as the reference 
category. Potential confounding by maternal age, race/ethnicity, education, income, 
prepregnancy body mass index, folic acid use, alcohol intake, cigarette smoking, and 
prepregnancy diabetes was evaluated by comparing Trimester 1 ORs adjusted for each factor 
to the corresponding unadjusted ORs. Maternal race/ethnicity (White non-Hispanic, 
Hispanic, African American non-Hispanic, and other), annual household income (<$10,000, 
$10,000–$49,999, ≥$50,000), use of folic acid supplements (any, none) and cigarette 
smoking (any, none) during the 2 weeks before through 14 weeks after the last menstrual 
period changed crude estimates more than 10% for at least one specific defect and were 
controlled as potential confounders in all multivariable models. Two approaches were used 
to estimate ORs. First, conventional (frequentist) ORs and 95% CIs were calculated using 
logistic regression for Trimester 1 exposures. In analyses of specific AEDs, models included 
a term for use of any other AED during Trimester 1 in an effort to control for confounding 
by polytherapy. The frequentist approach assumes no prior information and that the true OR 
could be any value. Given the extensive literature to date on the association between use of 
AEDs and birth defects and treatment guidelines (13, 14), it is highly unlikely that the true 
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OR could be any value. We, therefore, employed a second approach for OR estimation, a 
“prior data method” (15), which adds a Bayesian perspective to conventional, frequentist 
analyses by incorporating prior knowledge (“priors”). Three assessors–a clinical teratologist 
(LBH), a pharmaco-epidemiologist (AAM), and a birth defects epidemiologist (MMW)– 
were asked to provide what they thought were the minimum and maximum risk ratio values 
and their level of certainty in these values for each AED–defect combination. These risk 
ratio values were converted to 95% certainty intervals and combined into summary priors 
using geometric mean averaging, which were used to create approximately 200,000 
hypothetical observations that would produce the summary prior OR and 95% boundaries. 
Posterior ORs (pORs) and 95% posterior intervals were calculated as weighted averages of 
the observed and hypothetical data. Some specific medication and birth defect associations 
had missing summary priors because assessors felt information was insufficient to form a 
judgment. In this situation, posterior and frequentist results would be equivalent and no 
pORs were calculated.
RESULTS
Distributions of epilepsy history and AED use in mothers of all birth defect cases and 
controls are shown in Table 1. Among women with Trimester 1 use and epilepsy or seizure 
history, carbamazepine was the most commonly reported drug, followed by valproic acid, 
phenytoin, and phenobarbital. Among women without a history of seizures, 0.4% reported 
Trimester 1 use of an AED for other indications (e.g., bipolar disorder, depression, pain). 
Subsequent analyses of Trimester 1 use combined women with and without epilepsy/seizure 
histories. AED use only outside Trimester 1 without a history of seizures (Pre/Post Use + No 
Seizure History) was reported by approximately 0.2% of both case and control mothers, 
respectively.
Among cases, sociodemographic and behavioral risk factors, for the most part, did not differ 
appreciably between mothers in the Trimester 1 exposure group and mothers in the No 
Seizures or Use group (Table 2). Trimester 1–exposed women were more likely to be White 
non-Hispanic, have lower family incomes, use folic acid, and smoke cigarettes. The 
distributions of maternal demographic and behavioral factors among NTD, OC, HD, and 
hypospadias cases and non-malformed controls have been previously published (16–19).
Table 3 shows the crude ORs using the conventional frequentist method for cases of NTDs, 
OCs, HDs, hypospadias, and other birth defects in relation to any Trimester 1 use, Trimester 
1 Non-exposed + Epilepsy, and Pre/Post Use + No Seizure History. Women with Trimester 1 
use were more likely to have a pregnancy affected by an NTD [adjusted OR (aOR) 2.2; 95% 
CI, 1.2–3.9], OC (1.7; 1.1–2.8), or HD 1.5 (1.0–2.2) compared with no seizures or use 
women. In contrast, women in the Trimester 1 Non-exposed + Epilepsy group did not seem 
to have increased risks in any birth defect group. Hypospadias and other birth defects were 
not associated with Trimester 1 use. When analyses were restricted to isolated cases of birth 
defects, only the relationship between any Trimester 1 use and NTDs changed appreciably, 
decreasing to 1.6 (0.82–3.3).
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Trimester 1 use of some specific AEDs showed strong relationships, based on adjusted 
frequentist analyses, to specific birth defects (Table 4). Valproic acid-exposed mothers were 
9.7 (3.4–27.5) times more likely to have a child with an NTD and 4.4 (1.6–12.2) times more 
likely to have a child with an OC; aOR for HDs, hypospadias, and other birth defects were 
also elevated, but the lower confidence bounds were below 1.0. Carbamazepine use was 
associated with NTDs (aOR, 5.0; 1.9–12.7), but not with other specific defects. Phenytoin 
and lamotrigine did not show any associations with birth defect groups, although the 
numbers of exposed cases and controls were small owing to less frequent use. 
Benzodiazepine use was not examined because most use was not for treatment of seizures.
Table 4 also includes the adjusted pORs. For the most part, frequentist ORs did not differ 
appreciably from summary priors. Hence, pORs, which reflect the combination of observed 
data and priors, were generally similar to the frequentist ORs, but with narrower CIs. For 
example, under frequentist theory, the observed association between NTDs and valproic acid 
exposure estimated that 95 out of 100 repeated studies would show a 3.4- to 27.5-fold 
increased risk, whereas the pORs were somewhere between 5.4- and 19.8-fold. Analyses 
based on the Greenland approach resulted in not only more stable, but stronger, relationships 
for some medication–birth defect comparisons: Carbamazepine and NTDs (pOR, 5.0; 2.3–
10.8); valproic acid and HDs (pOR, 2.4; 1.1–5.3), and valproic acid and hypospadias (pOR, 
3.2; 1.2–9.0).
The vast majority of Trimester 1 use case and control mothers were exposed to AED 
monotherapy. A subanaly-sis of mothers on monotherapy, as a proxy for less severe or better 
controlled epilepsy, revealed no appreciable change in Trimester 1 use unadjusted frequentist 
ORs for OCs, HDs, hypospadias, and other birth defect groups, with one possible exception: 
The OR for NTDs decreased to 1.6 (95% CI, 0.80–3.1). Polytherapy was reported by the 
mothers of 4 of 15 Trimester 1–exposed NTDs versus 4 of 43 controls; corresponding 
numbers for OCs were 5 of 30 versus 4 of 43; 7 of 71 HDs versus 4 of 42; 0 of 8 hypo-
spadias versus 3 of 25; and 6 of 42 other birth defects versus 3 of 41. Valproic acid in 
combination with another AED was reported by mothers of 2 NTDs, 3 OCs, 3 HDs, 0 
hypospadias, 2 other birth defects, and 1 of each control group.
A subanalysis of women with Trimester 1 exposure without a seizure history was conducted 
to evaluate confounding by indication (data not shown). In this subgroup, there were no 
cases exposed to lamotrigine and no NTD, cleft, or hypospadias cases exposed to 
carbamazepine or phenytoin. For HDs, frequentist, unadjusted ORs were below 1.0 for 
valproic acid, carbamazepine, and phenytoin. Frequentist, unadjusted ORs for valproic acid 
exposure without a seizure history were 5.6 (1.1–27.7) for NTDs, 4.2 (1.0–17.7) for clefts, 
and 2.6 (0.36–18.3) for hypospadias.
DISCUSSION
The effect of AED exposure in early gestation on risk of birth defects seems to depend on 
both the specific agent and the specific outcome. Associations with valproic acid exposure 
were most notable in terms of strength and breadth, appearing to increase the risk of NTDs, 
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OCs, HDs, and, possibly, hypospadias. Carbamazepine exposure, on the other hand, was 
only associated with an increased risk of NTDs.
The varied pattern of risks across AEDs and birth defects suggests teratogenicity of drug 
rather than disease. First, several of our findings argue against confounding by underlying 
disease: Drug-specific increased risks were independent of the effects of other types of 
AEDs used during the first trimester and of epilepsy history without drug exposure. Next, 
epilepsy history without AED use did not seem to increase the risk of any birth defect. Also, 
valproic acid use for indications other than seizures was associated with increased risks of 
NTDs and clefts, and possibly hypospadias. Finally, the observed positive associations were 
not confined to the presumably more severely affected women who were on polytherapy.
Many of the previous studies have included small numbers, limiting analyses to risks of all 
birth defects as a single outcome (20–26) or to all AEDs in relation to specific birth defect 
groups (27). The studies that have examined specific birth defect cases exposed to specific 
AEDs (4, 8, 9, 23, 28–33) have also been limited by small numbers, but their findings have 
suggested increased risks similar to those observed in the present study. Three studies had 
numbers of exposed cases similar to or greater than those in our analyses (14, 33–35) and 
showed strikingly similar patterns of increased risks, including positive associations between 
valproic acid and NTDs, OCs, HDs, and hypospadias as well as suggestions for a positive 
association between carbamazepine and NTDs. Clinical guidelines have recently been 
published that take these previous studies into account and suggest avoidance of valproic 
acid, carbamazepine, and phenytoin in pregnancy, if possible (13). Findings from the present 
study support the recommendations for valproic acid and carbamazepine, but use of 
phenytoin was less common, which limited our ability to detect associations with specific 
birth defects. Use of lamotrigine was so low, with fewer than five cases in any one defect 
group, that our data cannot stand alone to indicate risk or safety in relation to these 
outcomes.
The frequentist approach assumes that the true association could lie anywhere between 0 and 
infinity. However, interpretation of the many previous studies and clinical impressions 
strongly suggests this assumption is wrong. The Greenland approach incorporates this prior 
knowledge into our analyses. The compatibility of the previous and our present findings is 
evidenced in the general similarity amongst frequentist, summary prior, and pORs. The 
summary priors took into account the viewpoints of three assessors: A clinical geneticist 
with decades of clinical and research expertise on this topic, a pharmaco-epidemiologist 
with a critical view of study design and related research findings, and a birth defects 
epidemiologist who conducted a quantitative review of the literature. Each assessor was 
given equal weight to balance the different viewpoints, although there was remarkable 
similarity in their “priors” (data not shown).
Among women with a history of epilepsy, carbamazepine was the most frequently used 
AED in early pregnancy, as has been reported in European countries and Australia (8, 14, 
21, 32, 33). Some previous follow-up studies have suggested positive associations with birth 
defects (8, 9, 23, 25, 28, 33, 34), but were limited by not adjusting for potential confounding 
factors (20, 32–34) or were too small to evaluate the risk of specific malformations (9, 20, 
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23, 25). Our results suggest carbamazepine use increases the risk of NTDs but not OCs, 
HDs, or hypospadias. These results are consistent with findings reported from a large 
European case-control study (34). Although valproic acid is most notably associated with 
NTDs (36), our finding of a more generalized effect of this drug on birth defect risks has 
also been reported by others (3, 14, 32–34, 36). Previous reports suggest a teratogenic effect 
of phenytoin manifested in a syndrome involving growth retardation and dysmorphic facies 
and fingernails (25), outcomes that we could not evaluate in this study. Evidence, including 
our observations, is lacking to suggest an association between phenytoin and specific major 
malformations, such as NTDs, OCs, HDs, and hypo-spadias (34, 36, 37). Lamotrigine use 
was reported by only 13 of 119 Trimester 1 AED users (11 cases and 2 controls) in the 
NBDPS, but use is increasing both in Europe and the United States (4, 38). NTDs, OCs, and 
HDs have been reported in lamotrigine-exposed pregnancies in higher frequencies than 
might be expected (4, 39). A case-control study reported no difference in the prevalence of 
lamotrigine exposure between mothers of OC cases and controls with other birth defects 
(40).
The possibility of confounding by underlying epilepsy was raised when early studies 
suggested increased risks (albeit without statistical significance) (20, 26, 41). More recent 
studies and our results provide evidence that untreated epilepsy is not associated with 
increased risks of birth defects (10, 20, 25, 42, 43). In the present study, untreated epilepsy 
was identified by maternal report, not by physician diagnosis, and no detailed information 
was collected on epilepsy history. A previous prospective investigation of epilepsy in 
pregnancy found that neurology records often did not confirm a woman’s report of either 
epilepsy or seizure history (25). Assuming this inaccuracy is greatest for women who 
reported a history of seizures but no diagnosis of epilepsy, we excluded such women who 
reported no AED use from analyses. It is likely, however, that the Trimester 1 Non-exposed 
+ Epilepsy group also includes women who only experienced childhood febrile seizures, had 
mild epilepsy, or did not have epilepsy during pregnancy, limiting our ability to make 
inferences about our findings for this group of women. In addition, although use of 
carbamazepine, phenytoin, and lamotrigine for indications other than seizures was too low to 
evaluate, use of valproic acid among women without a seizure history increased risks of 
NTDs, clefts, and possibly hypospadias in magnitudes similar to overall use.
Increased risks of birth defects associated with polytherapy have been shown in several 
studies (8, 14), but closer examination suggests that if polytherapy does not include valproic 
acid, risks are similar to those associated with mono-therapy (14, 24). We were not able to 
analyze women on polytherapy separately because of small numbers. However, results for 
women on monotherapy during Trimester 1 were similar to those for women on either 
monotherapy or polytherapy during Trimester 1. Furthermore, the associations for specific 
AEDs were adjusted for the effects of use of other such agents as a way to control for overall 
poly-therapy, but not specific combinations of AEDs.
Among all birth defects included in NBDPS, NTDs, OCs, HDs, and hypospadias were 
selected as specific case groups because they have been reported as being associated with 
AEDs in previous studies. To reduce etiologic heterogeneity, NBDPS restricts cases to those 
without a known chromosomal or single gene disorder. In this analysis, cases were restricted 
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to those without a known family history for the same reason. Isolated defects may also be 
distinct from those that occur with other types of major malformations. Subanalyses of 
isolated case groups showed similarly elevated ORs to those of the overall case groups, but 
corresponding analyses of the various combinations of defects in the nonisolated case groups 
were not performed owing to small numbers. The HD case group includes a wide range of 
specific defects that likely vary in etiology. Although numbers were too small to evaluate 
specific HDs, the types of HDs among valproate, carbamazepine-, phenytoin-, and 
lamotrigine-exposed subjects were evaluated and no pattern of single or set of HDs was 
observed.
The NBDPS offered a large dataset to evaluate specific AED use in relation to specific birth 
defects, but this case-control study is limited to maternal recall of exposures. Retrospective 
recall accuracy of prescription medications, particularly those that are used for long 
durations like AEDs, has been shown to be high (44), suggesting that the observed findings 
for medications are less vulnerable to information bias. In this study, there was little 
measured confounding by demographic and behavioral factors, although confounding by 
unmeasured or inaccurately measured factors is a possibility. For example, folic acid use in 
early gestation was controlled as a potential confounder, but dose was not measured. If AED 
users were more likely to take higher doses of folic acid, which corresponded with a greater 
reduction in birth defect risks, there would be negative confounding and observed ORs 
would underestimate the true effect. Also, pregnancy terminations were incompletely 
ascertained in NBDPS; if Trimester 1 AED users are more likely or less likely than nonusers 
terminate a pregnancy when a birth defect is diagnosed prenatally, selection bias could 
occur. Similarly, if Trimester 1 AED exposure is associated with study participation 
differentially between case and control mothers in general, selection bias could result. 
However, the consistency of observed findings with prior findings suggests that such 
selection biases, if present at all, are not a major influence.
Epilepsy in pregnancy is a difficult condition to manage for many reasons. First, although 
many (but not all) of the AEDs that might be used to control seizures carry teratogenic risks, 
which vary across specific AEDs, there is insufficient information available on the full range 
of defects in relation to the full range of AEDs. Further, the choice of AED for a given 
patient is influenced by the type of epilepsy and the woman’s response to particular drugs, 
as well as factors such as nonadherence. Because the adverse effect of seizures occurring 
during pregnancy cannot be ignored, the absolute increase in risk for one or more defects 
must be balanced against the need to maintain adequate control of a pregnant woman’s 
epilepsy. Thus, further studies are needed to identify AEDs with the lowest teratogenic risks 
in order to facilitate more fully informed risk–benefit decisions by epileptic women and their 
health care providers regarding the choice of AEDs in pregnancy.
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Selected Abbreviations and Acronyms
AEDs anti-epileptic drugs
aOR adjusted odds ratio
CI confidence interval
HD heart defect
NBDPS National Birth Defects Prevention Study
NTDs neural tube defects
OCs oral clefts
OR odds ratio
pORs posterior odds ratios
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FIGURE 1. 
Flow diagram of seizure history, epilepsy diagnosis, and anti-epileptic drug (AED) use 
among case and control mothers.
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TABLE 1
Maternal antiepileptic drug (AED) use according to timing, epilepsy or seizure history, specific drug, and case/
control status
Cases (n = 18,182) Controls (n = 6622)
Epilepsy and seizure history and AED use n % n %
Unexposed
 No history of seizure and no AED use 17,899 98.44 6,527 98.55
Trimester 1 use
 Total 172 0.95 46 0.69
 Any history of seizure 98 0.54 21 0.32
  Carbamazepine* 31 0.17 8 0.12
  Valproic acid 30 0.16 3 0.05
  Phenytoin 20 0.11 4 0.06
  Phenobarbital 19 0.10 0 0.00
  Lamotrigine 11 0.06 2 0.03
  Benzodiazepine 2 0.01 3 0.05
  Neurontin 4 0.02 1 0.02
  Levetiracetam 4 0.02 1 0.02
  Topiramate 2 0.01 1 0.02
  Primidone 2 0.01 0 0.00
  Not otherwise specified 0 0.00 1 0.02
 No history of seizure 74 0.41 25 0.38
  Carbamazepine 2 0.01 2 0.03
  Valproic acid 19 0.10 3 0.05
  Phenytoin 4 0.02 2 0.03
  Benzodiazepine 39 0.21 16 0.24
  Neurontin 8 0.04 1 0.02
  Topiramate 5 0.03 1 0.02
Pre/post use + no seizures
 AED use only before or after Trimester 1 and no seizure history 37 0.20 10 0.15
Trimester 1 non-exposed + epilepsy
 Epilepsy history and no AED use in Trimester 1 74 0.41 39 0.59
AED use includes polytherapy; excludes 15 cases and 10 control with unknown seizure history and 421 cases and 113 controls with seizure history, 
no diagnosis of epilepsy and no AED use.
*
Includes oxcarbamazepine.
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TABLE 2
Maternal demographic and behavioral factors among birth defect cases
Trimester 1 use* cases (n = 172) No seizures or use† cases (n = 17,899)
Maternal factors n % n %
Age (y)
 <20 10 5.7 1936 10.8
 20–24 34 19.4 4157 23.2
 25–29 52 29.7 4597 25.7
 30–34 46 26.3 4454 24.9
 ≥35 30 17.1 2754 15.4
 Missing 0 0.0 1 0.0
Race/ethnicity
 White non-Hispanic 132 75.4 10,601 59.2
 Hispanic 17 9.7 4251 23.8
 African American non-Hispanic 13 7.4 1817 10.2
 Asian/Pacific Islander/American Indian/Other 10 5.7 1176 6.6
 Missing 0 0.0 54 0.3
Education (y)
 ≤12 80 45.7 7869 44.0
 >12 91 52.0 9913 55.4
 Missing 1 0.6 117 0.7
Annual household income ($)
 <10,000 46 26.3 3840 21.5
 10,000–49,999 66 37.7 7951 44.4
 ≥50,000 57 32.6 5623 31.4
 Missing 3 1.7 485 2.7
Prepregnancy body mass index (kg/m2)
 <18.5 11 6.3 958 5.4
 18.5–24.9 79 45.1 9037 50.5
 25.0–29.9 38 21.7 3904 21.8
 ≥30 41 23.4 3254 18.2
 Missing 3 1.7 746 4.2
Folic acid use‡
 Any 153 87.4 15,218 85.0
 None 14 8.0 2398 13.4
 Missing 5 2.9 283 1.6
Alcohol‡
 Any 58 33.1 6460 36.1
 None 110 62.9 11,280 63.0
 Missing 4 2.3 159 0.9
Cigarettes†
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Trimester 1 use* cases (n = 172) No seizures or use† cases (n = 17,899)
Maternal factors n % n %
 Any 60 34.3 3674 20.5
 None 111 63.4 14,140 79.0
 Missing 1 0.6 85 0.5
Prepregnancy diabetes types I or II
 Yes 5 2.9 394 2.2
 No 167 95.4 17,489 97.7
 Missing 0 0.0 16 0.1
*Any anti-epileptic drug use Trimester 1.
†No anti-epileptic drug use during the 3 months before or during pregnancy.
‡
During 1 month before through Trimester 1.
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